Loading...
  • chemotherapy
  • Our cell therapy results compare favorably with historical median survival times (up to 9 months) and disease-free intervals (up to 7.5 months) of dogs with osteosarcoma receiving standard therapy (surgery and chemotherapy) and support the effectiveness of adjuvant TALL-104 cell administration in preventing or delaying disease recurrence in these dogs. (aacrjournals.org)
  • As described in this report, TALL-104 cells given as a single agent after surgery and CDDP chemotherapy resulted in a significant antitumor activity in dogs with osteosarcoma (median ST = 11.5 months). (aacrjournals.org)
  • activity
  • Furthermore, mice that rejected CMS4 following a single adoptive transfer of CTL displayed antitumor activity to a rechallenge 45 days later, not only in the lung, but also at a s.c. distal site. (jimmunol.org)
  • Gately MK, Warrier RR, Honasoge S, Carvajal DM, Faherty DA, Connaughton SE, Anderson TD, Sarmiento U, Hubbard BR, Murphy M (1994) Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. (springer.com)
  • subsets
  • These subsets were then infused into mice with B16F10 melanoma that were lymphoreplete [no total body irradiation (TBI)], or lymphodepleted with nonmyeloablative (5 Gy) or myeloablative (9 Gy with hematopoietic stem cell transplantation) TBI. (aacrjournals.org)
  • 2017
  • This Focussed Research Review is based on a presentation given at the 3rd Symposium on " Advances in Cancer Immunology and Immunotherapy ", held in Athens, Greece, November 2nd- 4th, 2017. (springer.com)
  • Vaccine
  • We found that cyclophosphamide, paclitaxel, and doxorubicin, when given in a defined sequence with a GM-CSF-secreting, neu-expressing whole-cell vaccine, enhanced the vaccine's potential to delay tumor growth in neu transgenic mice. (aacrjournals.org)
  • We have previously demonstrated delayed tumor development after combining debulking surgery with antitumor immunotherapy [7 and successfully used autologous tumor lysate as an effective anti-cancer vaccine [1, (docplayer.net)
  • therapeutic
  • Overall, these data suggest that the adoptive transfer of tumor-specific CTL may have therapeutic potential for malignancies that proliferate in or metastasize to the lung. (jimmunol.org)
  • The therapeutic effect of IT-EP/IL12 was absent in perforin-deficient mice, indicating that tumor elimination occurred through conventional perforin/granzyme lysis by CTLs. (springer.com)
  • Synergetic targeting without eliciting systemic toxicity achieved by integration of antiangiogenic and immunotherapy in a single nanoplatform is vital for therapeutic success. (springer.com)
  • Antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) are the major effector functions of many therapeutic antibodies, while these effects vary for different antibodies, and the treatment effectiveness is not certain. (mdpi.com)
  • Herein, we assess the biochemical role of IDO1 in tumor metabolism and immune surveillance, and review current diagnostic and therapeutic approaches that are intended to increase the effectiveness of immunotherapies against highly aggressive and difficult-to-treat IDO-expressing cancers. (frontiersin.org)
  • regression
  • In vivo, the adoptive transfer of CMS4-reactive CTL (≥1 × 10 6 ) resulted in nearly the complete regression of 3-day established lung metastases. (jimmunol.org)
  • therapy
  • In the last 10 - 30 years, targeting therapy for cancers has been developed and achieved enormous clinical effectiveness by transforming some previously deadly malignancies into chronically manageable conditions, but cure problem still remains. (scirp.org)
  • Thus, in an attempt to overcome the shortcomings of monoclonal antibody therapy and improve the treatment effectiveness, monoclonal antibody-based bispecific antibodies have been raised. (mdpi.com)